奥来鲁单抗
| 单克隆抗体 | |
|---|---|
| 种类 | ? |
| 目标 | NT5E（或叫CD73） |
| 临床资料 | |
| 其他名称 | MEDI9447 |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 1803176-05-7 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6348H9826N1710O1998S40 |
| 摩尔质量 | 143,350.81 g·mol−1 |
奥来鲁单抗（INN：oleclumab；开发代号：MEDI9447）是一种抗CD73人单克隆抗体，旨在治疗胰腺癌、结直肠癌和其他癌症。[1][2]
参考资料
[编辑]- ^ ClinicalTrial.gov for Oleclumab
- ^ Bendell, Johanna; LoRusso, Patricia; Overman, Michael; Noonan, Anne M.; Kim, Dong-Wan; Strickler, John H.; Kim, Sang-We; Clarke, Stephen; George, Thomas J.; Grimison, Peter S.; Barve, Minal. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer immunology, immunotherapy: CII. 2023-07, 72 (7). ISSN 1432-0851. PMID 37016126. doi:10.1007/s00262-023-03430-6.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Oleclumab, American Medical Association.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
